Home › Compare › PARD vs FCPT

PARD vs FCPT: Dividend Comparison 2026

PARD yields 2000000.00% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PARD wins by $1.6247481716182984e+23M in total portfolio value
10 years
PARD
PARD
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full PARD calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — PARD vs FCPT

📍 PARD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPARDFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PARD + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PARD pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PARD
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, PARD beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PARD + FCPT for your $10,000?

PARD: 50%FCPT: 50%
100% FCPT50/50100% PARD
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

PARD
No analyst data
Altman Z
-88.2
Piotroski
2/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PARD buys
0
FCPT buys
0
No recent congressional trades found for PARD or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPARDFCPT
Forward yield2000000.00% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.8% ✓
Portfolio after 10y$1.6247481716182984e+23M$49.1K ✓
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00 ✓$5,775.28
Total dividends collected$1.6146053563276882e+23M$24.1K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PARD vs FCPT ($10,000, DRIP)

YearPARD PortfolioPARD Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,401$700.92+$100.00M → PARD
2$467,446,731,075$467,339,719,626.17$13,064$864.84+$467446.72M → PARD
3$1,021,215,363,816,662$1,020,715,195,814,411.90$15,051$1,072.48+$1021215363.80M → PARD
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$17,442$1,337.22+$1043112617104.09M → PARD
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$20,340$1,677.08+$498482143759731.38M → PARD
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$23,880$2,116.57+$111599275650097776.00M → PARD
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$28,241$2,689.36+$11738678336351557632.00M → PARD
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$33,660$3,442.07+$583674362697175072768.00M → PARD
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$40,456$4,439.95+$1.3894210989607547e+22M → PARD
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$49,063$5,775.28+$1.6247481716182984e+23M → PARD

PARD vs FCPT: Complete Analysis 2026

PARD — Stock

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Full PARD Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this PARD vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PARD vs SCHDPARD vs JEPIPARD vs OPARD vs KOPARD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.